ASH 2022 | Clinical trials aiming to reduce the toxicity of novel agents in AML

In this video, Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, discusses efforts to reduce the toxicity of novel agents in acute myeloid leukemia (AML) presented at the 2022 ASH Annual Meeting. Prof. Wei highlights several trials, including the DaunoDouble trial (NCT02140242), which evaluated whether 60 or 90mg/m2 is the optimal dose of daunorubicin for induction, and whether one or two inductions are required for optimal outcomes. Following this, Prof. Wei highlights the AML19 trial (ISRCTN78449203) which explored whether FLAG-idarubicin is superior to daunorubicin-araC and whether combining this with two doses of gemtuzumab ozogamicin (GO) would be more beneficial than one. To conclude, other studies in this space are discussed, including the CAVEAT trial (ACTRN12616000445471), and the VALDAC trial (ACTRN12619000746134). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.